Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Eye symbols : Abbv save search
Global OTC Artificial Tears Analysis Report 2023-2030: The Influence of Smart Technologies, Market Positioned for Continued Expansion Amid Growing Focus on Eye Wellness
Published: 2024-03-21 (Crawled : 00:00) - prnewswire.com
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 0.17%
H: 0.28%
C: -0.01%
JNJ | $144.45 -2.13% 0.03% 13M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
BHC | $8.74 1.28% 0.11% 2.5M
|
Health Technology
|
| O: -0.74%
H: 1.54%
C: 1.38%
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
report expansion global wellness smart growing eye market
Dry Eye Syndrome Drugs Market to grow by USD 2,159.21 million from 2022 to 2027; The growing geriatric population drives the market - Technavio
Published: 2023-08-09 (Crawled : 08:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.92%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.11%
H: 0.53%
C: 0.53%
VTRS | $11.12 -1.77% -1.8% 6.8M
|
Health Technology
|
| O: 0.0%
H: 2.96%
C: 0.99%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: -0.07%
H: 0.73%
C: 0.36%
GSK | $39.95 -1.36% 0.0% 2.4M
|
Health Technology
|
| O: 0.14%
H: 0.8%
C: 0.43%
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
ABT | $109.21 0.29% 0.34% 7.3M
|
Health Technology
|
| O: -1.71%
H: 0.0%
C: 0.0%
growing eye market
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain
Published: 2023-05-23 (Crawled : 15:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: -0.62%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -1.22%
GKOS M | $96.95 0.11% 0.0% 430K
|
Health Technology
|
| O: -0.71%
H: 2.06%
C: -1.05%
BHC | $8.74 1.28% 0.11% 2.5M
|
Health Technology
|
| O: -2.27%
H: 4.24%
C: -2.21%
ALC | $79.61 -1.83% 0.0% 1.1M
|
Health Technology
|
| O: -0.51%
H: 0.02%
C: -3.25%
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: -0.31%
H: 0.26%
C: -1.34%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
OCUL | $7.8 0.0% 1.3M
|
Health Technology
|
| O: 4.45%
H: 7.65%
C: 2.21%
GRFS | $6.78 3.67% 3.54% 1.5M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -3.74%
ALDX 4 | $3.87 -6.97% -7.49% 720K
|
Health Technology
|
| O: 0.0%
H: 2.36%
C: 0.61%
pharma disease pipeline set eye trial
AbbVie, Capsida Set Sights on Gene Therapies for Eye Diseases
Published: 2023-02-23 (Crawled : 14:00) - biospace.com/
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: 0.15%
H: 1.77%
C: 0.78%
set eye
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
Published: 2023-02-23 (Crawled : 11:00) - prnewswire.com
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: 0.15%
H: 1.77%
C: 0.78%
abbvie collaboration genetic eye
Dry Eye Products Global Market Report 2022: Sector to Reach $9.68 Billion by 2028 at a 5.1% CAGR
Published: 2023-01-16 (Crawled : 20:00) - prnewswire.com
PBH | $68.06 -0.12% -1.68% 150K
|
Health Technology
|
| O: -0.27%
H: 1.52%
C: -0.9%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 2.34%
H: 0.04%
C: -0.87%
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: 0.13%
H: 0.85%
C: -0.63%
global report eye market
Dry Eye Products Market Worth $9.6+ Billion, Globally, by 2028 at 5+% CAGR | The Insight Partners
Published: 2022-10-14 (Crawled : 11:00) - prnewswire.com
PBH | $68.06 -0.12% -1.68% 150K
|
Health Technology
|
| O: 0.45%
H: 0.39%
C: -1.63%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 0.17%
H: 0.8%
C: -0.75%
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: -0.22%
H: 1.32%
C: 0.24%
eye market
Uveitis Drugs Market, High Prevalence Of Eye Disorders And Associated Risk Factors Of Uveitis to Boost Market Growth - Technavio
Published: 2022-08-08 (Crawled : 22:00) - prnewswire.com
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 1.28%
H: 0.8%
C: 0.13%
BHC | $8.74 1.28% 0.11% 2.5M
|
Health Technology
|
| O: -7.02%
H: 7.55%
C: -4.6%
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: 0.24%
H: 1.11%
C: -0.31%
BIIB | $195.16 -0.83% -0.85% 870K
|
Health Technology
|
| O: -0.56%
H: 1.04%
C: 0.58%
AMGN | $265.64 0.05% 0.05% 2M
|
Health Technology
|
| O: -0.03%
H: 1.02%
C: 0.47%
risk eye growth market
Allergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Published: 2022-04-28 (Crawled : 13:20) - biospace.com/
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: 0.0%
care research eye
FDA Approves JUVÉDERM® VOLBELLA® XC For Undereye Hollows
Published: 2022-02-08 (Crawled : 19:00) - biospace.com/
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
derm fda eye
VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available
Published: 2021-12-09 (Crawled : 20:00) - biospace.com/
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: 0.28%
H: 1.84%
C: 1.59%
fda eye drop presbyopia
Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting
Published: 2021-11-08 (Crawled : 15:00) - biospace.com/
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
eye
U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision)
Published: 2021-10-29 (Crawled : 22:00) - prnewswire.com
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
| Email alert
Add to watchlist
food eye drop drug presbyopia
AbbVie and REGENXBIO Announce Eye Care Collaboration
Published: 2021-09-13 (Crawled : 11:00) - prnewswire.com
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: 0.67%
H: 1.29%
C: 0.08%
RGNX | $17.49 -2.94% -3.03% 300K
|
Health Technology
|
| O: 21.86%
H: 9.05%
C: 7.66%
CLSD | $1.165 -9.69% -10.73% 330K
|
Health Technology
|
| O: 0.3%
H: 4.82%
C: 2.72%
eye collaboration
New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition
Published: 2021-07-25 (Crawled : 16:20) - prnewswire.com
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
| Email alert
Add to watchlist
treatment eye potential presbyopia
Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting
Published: 2021-07-20 (Crawled : 13:00) - biospace.com/
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: 0.11%
H: 1.89%
C: 0.43%
eye
Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting
Published: 2021-04-27 (Crawled : 13:00) - biospace.com/
ABBV | $162.54 0.54% 0.0% 4.8M
|
Health Technology
|
| O: -0.13%
H: 0.54%
C: 0.17%
eye test research
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.